Key result
Treatment with pdVWF/FVIII-C achieved 100% excellent and/or good clinical efficacy for on-demand and prophylaxis treatment in patients with von Willebrand disease over 12 months.
Why the study?
This study was conducted to assess the safety and efficacy associated with long-term real-world experience of the pdVWF/FVIII-C, Fanhdi, in patients with von Willebrand disease.
Does pdVWF/FVIII-C provide safe and effective hemostasis in adult patients with von Willebrand disease?
Population
15 VWD patients at 5 centers in Spain
Comparison
pdVWF/FVIII-C for on-demand and prophylaxis treatment
Design
Observational, prospective, post-authorization multicenter cohort study
Follow-up
12 months
Authors
Loading...
May support pdVWF/FVIII-C hemostasis in VWD; leaves open need for randomized confirmation in larger cohorts.
Cohort (n=15)
Yes
Does pdVWF/FVIII-C provide safe and effective hemostasis in adult patients with von Willebrand disease?
Real-world use of pdVWF/FVIII-C in patients with von Willebrand disease is safe and highly effective for both on-demand and prophylactic treatment of bleeding.
Benítez et al. (2025) conducted a cohort in von Willebrand disease (n=15). pdVWF/FVIII-C (Fanhdi) was evaluated on Overall clinical efficacy of treatment (excellent and/or good response). Treatment with pdVWF/FVIII-C achieved 100% excellent and/or good clinical efficacy for on-demand and prophylaxis treatment in patients with von Willebrand disease over 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: